Christine Chevreau

London Rebuilding Society — United Kingdom

Medicine · Health Sciences

71h-index27.9kcitations493works7.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(223), Renal cell carcinoma treatment(100), Vascular Tumors and Angiosarcomas(66), Testicular diseases and treatments(62), Cancer Genomics and Diagnostics(50)

Publications492 total

Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)”
Annals of Oncology·2025
Insights Into Non‐Classic Primary Bone Sarcomas in Children, Adolescents, and Young Adults: A French Descriptive Study
Pediatric Blood & Cancer·2025Open Access
PROPAN: Bayesian dose-finding of propranolol combined with metronomic fixed-dose cyclophosphamide based on bivariate efficacy-tolerability outcomes in patients with locally advanced or metastatic angiosarcoma (LAMA): A phase I-II sequential trial by the French Sarcoma Group.
Journal of Clinical Oncology·2025
Treatment of poor-risk non seminomatous germ-cell tumors (NSGCT) adapted by tumor marker decline: A 7-year multicenter real-world experience.
Journal of Clinical Oncology·2025· 1 cited
Actualisation des recommandations pour la prise en charge et le traitement des tumeurs osseuses à cellules géantes de l’adulte – Place du dénosumab
Bulletin du Cancer·2025
Doxorubicin-Trabectedin With Trabectedin Maintenance in Leiomyosarcoma
Obstetrical & Gynecological Survey·2025
Cabozantinib in patients (pts) with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC): Results of the multicenter CABRAMET phase II trial (NCT03967522).
Journal of Clinical Oncology·2025· 3 cited
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
New England Journal of Medicine·2024· 69 citedOpen Access
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
Journal of Clinical Oncology·2024· 13 cited
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
European Journal of Cancer·2024· 10 citedOpen Access
PEC‐PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent
Cancer·2024· 5 citedOpen Access
Impact de la TEP-TDM au 18F-FDG sur la prise en charge des sarcomes des tissus mous de l’adulte en situation initiale ou de récidive
Médecine Nucléaire·2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study
European Journal of Cancer·2024· 2 cited
Management of tumor volume changes during preoperative radiotherapy for extremity soft tissue sarcoma: a new strategy of adaptive radiotherapy
Radiology and Oncology·2023· 6 citedOpen Access
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma
Journal for ImmunoTherapy of Cancer·2023· 12 citedOpen Access
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study
British Journal of Cancer·2023· 28 citedOpen Access
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
The Lancet Oncology·2023· 29 cited
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial
European Urology Oncology·2023· 5 cited
1913O A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
Annals of Oncology·2023· 6 citedOpen Access
Leiomyosarcoma and liposarcoma in young patients: The national netsarc+ network experience
EJC Paediatric Oncology·2023· 1 citedOpen Access
page 1 of 25Next →

Frequent Co-authors

Jean‐Yves Blay(26), Nicolas Penel(21), Sophie Piperno‐Neumann(18), Nicolás Isambert(18), Emmanuelle Bompas(18), Antoîne Italiano(18), Florence Duffaud(14), Bernard Escudier(13), François Bertucci(13), Didier Cupissol(11), Axel Le Cesne(11), Alain Ravaud(10), Olivier Collard(10), Axel Le Cesne(9), David Pérol(9), Sylvie Négrier(8), Isabelle Ray‐Coquard(8), María Rios(8), Isabelle Ray‐Coquard(8), Corinne Delcambre(8)